Jorge R. Barrio

University of California, Los Angeles — United States

Medicine · Health Sciences

70h-index18.4kcitations386works11.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(97), Alzheimer's disease research and treatments(61), Fluorine in Organic Chemistry(48), Dementia and Cognitive Impairment Research(46), Advanced MRI Techniques and Applications(33)

Publications385 total

Is US residence a risk factor for Alzheimer's disease?
Journal of Alzheimer s Disease·2025
History repeats itself: A new trivializing term for a potentially life-threatening side effect of antibody Alzheimer's disease therapy
Journal of Alzheimer s Disease·2025Open Access
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Advances in Alzheimer's disease·2024
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Journal of Alzheimer s Disease·2024· 7 cited
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Ageing Research Reviews·2024· 34 cited
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
International Journal of Molecular Sciences·2024· 36 citedOpen Access
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management
The Journal of Prevention of Alzheimer s Disease·2024· 1 citedOpen Access
Revision of Alzheimer’s diagnostic criteria or relocation of the Potemkin village
Ageing Research Reviews·2023· 8 citedOpen Access
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Ageing Research Reviews·2023· 46 cited
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
Diagnostics·2023· 22 citedOpen Access
The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Journal of Alzheimer s Disease·2023· 46 citedOpen Access
FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
Clinical Nuclear Medicine·2023· 14 citedOpen Access
Compositions for labeling .beta.-amyloid plaques and neurofibrillary tangles
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
8-fluoropurine compounds
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
In vivo imaging of sulfotransferases
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
Process for producing 8-fluoropurines
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
The anti-amyloid monoclonal antibody Lecanemab: 16 cautionary notes
Zenodo (CERN European Organization for Nuclear Research)·2023· 6 citedOpen Access
MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?
American Journal of Neuroradiology·2022Open Access
Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
Journal of Alzheimer s Disease·2022· 16 citedOpen Access
page 1 of 20Next →

Frequent Co-authors

Nagichettiar Satyamurthy(25), Michael E. Phelps(15), Vladimir Kepe(15), Gary W. Small(13), Linda M. Ercoli(9), Prabha Siddarth(9), Sung‐Cheng Huang(9), Sanjiv S. Gambhir(9), Harvey R. Herschman(9), Mohammad Namavari(8), Susan Y. Bookheimer(7), Michael E. Phelps(6), Karen J. Miller(5), S.C. Huang(4), Helen Lavretsky(4), Greg M. Cole(4), Meera Iyer(4), Eileen Bauer(4), Simon R. Cherry(4), Heinrich R. Schelbert(4)